

## **Dedication**

**To whom I shall beseech, pay my thanks and prayers, to finish this tremendous work, Allah the Almighty, praise be to Him.**

**To the soul of my beloved father, beloved compassionate mother, beloved wife, son, brothers, sister and beloved family.**

**To my faithful friends**

**To the free souls of scientists and students who have devoted themselves to science despite their severe sickness and obstacles.**

## Acknowledgments

Thank Allah

I would like to express my sincere gratitude to my supervisor, **Dr. Mohmaed El Mukhtar Abdelaziz** , for his constant support and faith that he gave me during my Ph.D work. It was his vision, patience, motivation, enthusiasm and tremendous knowledge that led me to my final destination.

My thanks are extended to my co/supervisor **Professor Zeid Abdullah Al-Othman** , Head Department of Chemistry School of science in The King Saud University for his constant motivation and support that he provided me during the entire process of my research. I am also thankful to all members of Advanced Materials Chair in The King Saud University, especially **Dr Ahmed Aquel, Prof A. Yacine Badjah-Hadj-Ahmed** and **Dr.Munir** for their constant motivation and support that they provided during the entire process of my research.

Furthermore, I gratefully acknowledge **Dr. Babiker Y. Abdulkhair** for his advice, supervision and crucial contribution in my research. His guidance helped me during all the time of my research. I could not have imagined having a better advisor and mentor for my PhD study, other than him.

## List of Abbreviations

AC	Affinity chromatography
ACN	Acetonitrile
AFM	Atomic force microscopy
AIBN	Azobisisobutyronitrile
BMA	Benzyl methacrylate
BP	Bonded phase
CLC	Capillary liquid chromatography
CE	Capillary electrophoresis
CEC	Capillary electrochromatography
CLSM	confocal laser scanning microscopy
CZN	Chlorzoxazone
DMSO	Dimethylsulfoxide
DVB	Divinyl benzene
EDMA	Ethylene dimethacrylate
ESI	Electrospray ionization
FDA	Food and Drug Administration
GC	Gas chromatography
GLP	Good laboratory practice
GMA	Glycidyl methacrylate
HETP	height of effective theoretical plate
HI	Hydrophobic interaction.
HMA	Hexyl methacrylate
HPLC	High performance liquid chromatography
ICH	International Conference on Harmonization
IE	Ion-exchange
i.d.	Internal diameter
IEC	Ion-exchange chromatograph
ISEC	Inverse size-exclusion chromatography
IS	Ion suppression
ISO	International Standards Organization
IP	Ion pair
LC	Liquid chromatography
LL	Liquid liquid
LOD	Limit of detection
LOL	Limit of linearity
LS	Liquid solid
LOQ	Limit of quantification
m-HPLC	micro high performance liquid chromatography
MC	Metal complexation
MIP	Mercury intrusion porosimetry
ML	Micellar liquid
MALDI	Matrix assisted laser desorption ionization
MS	Mass spectrometry
MWCNT	Multi-walled carbon nanotubes
NP	Normal phase
ODS	Octadecylsilica

PAR	Paracetamol
PEEK	Polyether etherketone
PLOT	Porous layer open tubular
PEO	Poly ethylene oxide
PTFE	Poly tetrafluoroethylene
ROMP	Ring opening metathesis polymerization
RP	Reversed phase
RSD	Relative standard deviation
SEC	Size-exclusion chromatography
SEM	Scanning electron microscopy
SE	Size-exclusion
SFC	supercritical fluid chromatography
SCOT	Support coated open tubular
TEM	Transmission electron microscopy
TGA	Thermogravimetric analysis
THF	Tetrahydrofuran
TMOS	Tetramethoxysilane
TMSM	3- trimethoxysilyl propyl methacrylate
TPB	total pore blocking
TRIM	Trimethylolpropane trimethacrylate
UPLC	Ultra performance liquid chromatography
USP	United States Pharmacopoeia
UV	Ultraviolet
VIS	Visible
WCOT	Wall coated open tubular

## ABSTRACT

This study has been focused on the development of an analytical method for the determination of Paracetamol (**PAR**) and Chlorzoxazone (**CZN**) in their combined pharmaceutical formulation using two stationary phases (home-made columns) which were prepared by two developed methods, one of which was in capillary column while the other was in conventional column.

The first preparation method was achieved using a home-made capillary column (0.10mm i.d. × 200mm length), filled with porous cross-linked hexyl polymethacrylate as monolithic stationary phase. The column morphology was characterized by scanning electron microscopy (SEM). The column showed perfect mechanical stability and permeability over the investigated flow range with regression factor  $R^2$  0.9994. The capillary column was used to separate PAR and CZN in their pharmaceutical formulation. The method proved to be simple, fast, sensitive, efficient, cost-effective and green approach owing is the combination of the amazing properties of a monolithic material and a miniaturized liquid chromatography, which reduces the analytical costs and the effect on the environmental impact of chromatographic applications. Both components were detected using a 3-nL nano-UV cell fixed at 270nm wavelength. The optimized mobile phase was composed of 1% aqueous formic acid solution and acetonitrile at 40:60 ratio, 1.0 $\mu$ L/min flow rate, 4.0nL injection volume and 50°C column temperature. Under the optimized conditions, PAR and CZN were separated in about 6.5min with chromatographic resolution of 2.37. Using the prepared column, the developed method was fully validated and compared with other reported works.

The second preparation method was achieved using also a home-made, conventional column (3.2 i.d., 100 mm length) which was a glycidyl polymethacrylate as monolithic stationary phase. The column morphology was characterized by scanning electron microscopy (SEM). The permeability was evaluated using acetonitrile and water as mobile phases, and uracil as un retained substrate. A simple and economical reverse phase high performance liquid chromatography (HPLC) method has been developed for the simultaneous estimation of PAR and CZN in their pharmaceutical formulations. Components were determined using a UV detector at 270 nm. The mobile phase was composed of 1% formic acid solution and acetonitrile (65:35 v/v), 0.7 mL/min flow rate and 5.0  $\mu$ L injection volume. The resolution between ingredients peaks was 1.96.

All findings proved that the both validated method using the prepared column is applicable for quality control and routine analysis of the two drugs.

## ABSTRACT (IN ARABIC)

لقد ركزت هذه الدراسة على تطوير طريقة تحليلية لتعيين تركيز كل من الباراسيتامول (PAR) و كلوروزوكسازون (CZN) في تركيبتيهما الصيدلانية وذلك بعد تطوير طريقتين لإعداد طورين مونولثين ثابتين في عموديين محليي الصنع ، أحدهما كان في العمود الشعري بينما الآخر في العمود التقليدي.

تمت طريقة التحضير الأولى باستخدام عمود شعري محلي الصنع (طول 200مم-نصف قطر داخلي 0.1مم) وتمت تعبئة العمود بمركب هكسيل-ميثا كريلات المستخدم كطور ثابت على شكل طور مترابط احادي. وقد استخدم المجهر الإلكتروني (SEM) لدراسة شكل العمود الذي اظهر استقرارًا ميكانيكيًا مثاليًا على مدى نطاق التحقيق مع عامل الانحدار  $R^2 = 0.9994$ . وقد تم استخدام العمود الشعري لفصل PAR و CZN في صيغتهما الصيدلانية. أثبتت الطريقة أنها بسيطة و سريعة و حساسة و فعالة ، واقتصادية ، وذلك لاستخدام كميات مصغرة من الطور المتحرك ، والتي تعتبر كخطوة نحو تقليل التكاليف التحليلية و التأثير البيئي للتطبيقات الكروماتوجرافية. تم الكشف عن كلا المكونين باستخدام خلية Nano-UV 3 nL عند طول موجة 270 نانوميتر. حيث كان الطور المتحرك يتكون من 1% محلول حمض فورميك مائي و اسيتونيتريل بنسبة 40:60 ، وكان معدل الانسياب 1.0 مايكروليتر/دقيقة وحجم الحقن 4.0 نانوليتر ودرجة حرارة العمود 50 درجة مئوية. تحت الظروف المثلى ، تم فصل PAR و CZN في حوالي 6.5 دقيقة مع درجة فصل 2.37. ويمكن استخدام هذه الطريقة الجديدة في التحاليل الروتينية بمصانع الادوية.

تمت طريقة التحضير الثانية باستخدام عمود تقليدي مصنوع محليًا (طوله 100 مم ، نصف قطره الداخلي 3.2مم) تم تعبئته بجليسيديل بوليميثاكريليت المستخدم كطور ثابت على شكل طور مترابط احادي. وقد اظهرت دراسة شكل العمود باستخدام المجهر الإلكتروني (SEM) استقرارًا ميكانيكيًا وقد تم تقييم النفاذية باستخدام الأسيتونتريل والماء كمراحل متنقلة ، واليوراسيل كمادة غير مستبقية. وتم تطوير طريقة تحليلية باستخدام جهاز كروماتوجرافيا ذات الاداء العالي (HPLC) لتحليل الانى لكل من PAR و CZN في تركيباتهما الدوائية. وذلك باستخدام مكشاف الأشعة فوق البنفسجية عند 270 نانومتر. و طور متحرك يتألف من 1% من محلول حمض الفورميك وأسيتونيتريل (65:35 v / v) ، ومعدل تدفق 0.7 مل / دقيقة وحجم الحاقن 5.0 ميكرو لتر. كانت درجة الفصل بين قمتي المكونين 1.96. ويمكن استخدام هذه الطريقة الجديدة في التحاليل الروتينية بمصانع الادوية.

## List of publications

**Some of the results presented in this thesis were published or accepted for publication as follows:**

**1- Salih, M. E.**, Aqel, A., Abdulkhair, B. Y., Alothman, Z. A., Abdulaziz, M. A., & Badjah-Hadj-Ahmed, A. Y. (2018). Simultaneous Determination of Paracetamol and Chlorzoxazone in Their Combined Pharmaceutical Formulations by Reversed-phase Capillary Liquid Chromatography Using a Polymethacrylate Monolithic Column. *Journal of Chromatographic Science*, 56(9), 819-827.. (Thomson and Reuters – ISI)

**2- Salih, M. E.**, Aqel, A., Abdulkhair, B. Y., Obbed M.S., Alothman, Z. A., Abdulaziz, M. A., & Badjah-Hadj-Ahmed, A. Y., Preparation and characterization of glycidyl polymethacrylate monolith column and its application for simultaneous determination of paracetamol and chlorzoxazone in their combined pharmaceutical formulations, accepted and under publication on *Journal of Analytical Chemistry*. (Thomson and Reuters –ISI)



## Table contents

	<b>Page</b>
<b>Dedication</b>	<b>i</b>
<b>Acknowledgments</b>	<b>ii</b>
<b>Abbreviations</b>	<b>iii</b>
<b>Abstract in English</b>	<b>v</b>
<b>Abstract in Arabic</b>	<b>vii</b>
<b>List of publications</b>	<b>viii</b>
<b>Table contents</b>	<b>ix</b>
<b>List of Tables</b>	<b>xii</b>
<b>List of Figures</b>	<b>xvi</b>
<b>Chapter (I) "Introduction and literature review "</b>	
<b>1.1 Introduction to HPLC</b>	<b>1</b>
<b>1.1.1 Separation mechanisms and LC modes</b>	<b>1</b>
1.1.1.1 Normal phase HPLC (NP-HPLC)	<b>2</b>
1.1.1.2 Reversed phase HPLC (RP-HPLC)	<b>4</b>
<b>1.1.2 Columns and stationary phases</b>	<b>5</b>
1.1.2.1 Type of packing materials (porous, nonporous, and monolithic)	<b>6</b>
1.1.2.3 Column dimensions	<b>7</b>
<b>1.2 Capillary Liquid Chromatography</b>	<b>8</b>
<b>1.2.1 Miniaturization LC</b>	<b>9</b>
<b>1.2.2 Advantages of using capillary LC</b>	<b>11</b>
<b>1.2.3 Capillary LC columns</b>	<b>12</b>
1.2.3.1 Packed capillary columns	<b>13</b>
1.2.3.2 Open tubular capillary columns	<b>14</b>
1.2.3.3 Monolithic capillary columns	<b>15</b>
<b>1.2.4 The capillary LC system</b>	<b>16</b>
1.2.4.1 Capillary LC pump	<b>16</b>
1.2.4.2 Sample injection of capillary LC	<b>17</b>
1.2.4.3 Capillary LC detectors	<b>19</b>
1.2.4.4 Capillary LC tubing and connectors	<b>21</b>
<b>1.3 Monolithic Materials and Preparation</b>	<b>23</b>
<b>1.3.1 Definition</b>	<b>23</b>
<b>1.3.2 Brief history</b>	<b>23</b>
<b>1.3.3 The causes and Impetus that led to the development of monoliths as stationary phases</b>	<b>26</b>
<b>1.3.4 Preparation of monolithic columns</b>	<b>28</b>
1.3.4.1 Preparation of inorganic monoliths	<b>29</b>
1.3.4.2. Preparation of organic polymer monoliths	<b>30</b>
<b>1.3.5 General properties and advantages of monolithic columns</b>	<b>37</b>
<b>1.3.6 Characterization of monolithic columns</b>	<b>43</b>
<b>1.4 Analytical Performance and Method Validation</b>	<b>46</b>
1.4.1 System suitability	<b>47</b>
1.4.2 Limit of detection (LOD)	<b>48</b>
1.4.3 Limit of quantitation (LOQ)	<b>48</b>

1.4.4 Linearity	48
1.4.5 Specificity and selectivity	49
1.4.6 Accuracy	49
1.4.7 Precision (Repeatability and/or Reproducibility)	50
1.4.8 Robustness	50
<b>1.5 Medical uses of Paracetamol and Chlorzoxazone</b>	<b>50</b>
<b>1.6 Overview on the Thesis</b>	<b>51</b>
1.6.1 Justification and aims of this work	51
<b>1.7 Literature review</b>	<b>53</b>
1.7.1 Preparation of monolith column and its application	53
1.7.2 Validation method of PAR and CZN	57
<b>Chapter .2 "Materials and methods"</b>	<b>60</b>
<b>2.1 Chemicals</b>	<b>60</b>
<b>2.2 Instruments.</b>	<b>60</b>
<b>2.3 Glassware and apparatus.</b>	<b>61</b>
<b>2.4 Methods.</b>	<b>62</b>
2.4.1 Preparation of Hexyl Methacrylate Capillary Monolithic Column.	62
2.4.2 Preparation of Glycidyl Polymethacrylate Stainless Steel Monolithic Column.	63
<b>2.5 Characterization.</b>	<b>64</b>
<b>2.5.1 Characterization of Hexyl Methacrylate Capillary Monolithic Column.</b>	<b>64</b>
2.5.1.1 Hydrodynamic properties and porosity.	64
2.5.1.2 Monoliths morphology	65
<b>2.5.2 Characterization of Glycidyl Polymethacrylate Stainless Steel Monolithic Column.</b>	<b>65</b>
2.5.2.1 Hydrodynamic properties and porosity.	65
2.5.2.2 Monoliths morphology	65
<b>2.6 Validation of assay method for Paracetamol and Chlorzoxazone using Capillary Monolithic Column</b>	<b>65</b>
2.6.1 Optimized chromatographic conditions	65
2.6.2 Standard Stock Solution	66
2.6.3 System Suitability	66
2.6.4 Linearity, LOD and LOQ	66
2.6.5 Specificity	66
2.6.6 Accuracy	67
2.6.7 Precision	67
2.6.8 Robustness	68
2.6.9 Assay of real samples	68
<b>2.7 Validation of assay method for Paracetamol and Chlorzoxazone using Stainless Steel Monolithic Column</b>	<b>69</b>
2.7.1 Optimized chromatographic conditions	69
2.7.2 Standard Stock Solution	69
2.7.3 System Suitability	69
2.7.4 Linearity, LOD and LOQ	69
2.7.5 Specificity	70
2.7.6 Accuracy	70
2.7.7 Precision	71

27.8 Robustness	71
2.7.9 Assay of real samples	72
<b>Chapter three "Results , Discussion and conclusion"</b>	<b>73</b>
<b>3.1 Characterization of the capillary monolithic column</b>	<b>73</b>
<b>3.2 Characterization of the stainless steel monolithic column</b>	<b>74</b>
<b>3.3 Validation results when using Capillary Monolithic Column</b>	<b>76</b>
3.3.1 System Suitability	76
3.3.2 Linearity, LOD and LOQ	77
3.3.3 Specificity	79
3, 3, 4 Accuracy	80
3.3.5 Precision	81
3.3.6 Robustness	84
3.3.7 Assay	92
<b>3.4 Validation results when using stainless steel Monolithic Column</b>	<b>92</b>
3.4.1 System Suitability	92
3.4.2 Linearity, LOD and LOQ	93
3.4.3 Specificity	95
3, 4, 4 Accuracy	96
3.4.5 Precision	97
3.4.6 Robustness	100
3.4.7 Assay	107
<b>3.5 Discussion</b>	<b>108</b>
3.5.1. Hexyl methacrylate monolithic capillary column	108
3.5.2 Glycidyl polymethacrylate monolithic stainless steel column	109
<b>3.6 Conclusion</b>	<b>112</b>
<b>Recommendations</b>	<b>113</b>
<b>References</b>	<b>114</b>
<b>Appendixes</b>	<b>129</b>

## List of Tables

<b>Table</b>	<b>Page</b>
Table 1.1 Names and definitions for HPLC techniques, relation between columns i.d., flow rate and sensitivity gain	10
Table: 3.1 acetonitrile flow rate ( $\mu\text{L}/\text{min}$ ) Vs Pressure drops across the capillary monolith column	76
Table: 3.2 acetonitrile and water flow rate ( $\mu\text{L}/\text{min}$ ) Vs Pressure drops across the stainless steel monolith column	73
<b>Tables obtained from Validation results when using capillary Monolithic Column</b>	
Table 3.3 System suitability results for paracetamol	76
Table 3.4 System suitability results for Chlorzoxazone	76
Table 3.5 Linearity result for paracetamol	77
Table 3.6 Linearity result for Chlorzoxazone	78
Table 3.7 Accuracy results for paracetamol and chlorzoxazone standards	80
Table 3.8 Accuracy results for paracetamol	80
Table 3.9 Accuracy results for chlorzoxazone	80
Table 3.10 Summary of accuracy results for paracetamol and chlorzoxazone	80
Table 3.11 intraday precision results for paracetamol and chlorzoxazone mixed standard.	81
Table 3.12 Intraday precision results for 80% paracetamol	81
Table 3.13 Intraday precision results for 100% paracetamol	81
Table 3.14 Intraday precision results for 120% paracetamol	82
Table 3.15 Intraday precision results for 80% chlorzoxazone	82
Table 3.16 Intraday precision results for 100% chlorzoxazone	82
Table 3.17 Intraday precision results for 120% chlorzoxazone	82
Table 3.18 Summary of intraday precision results for paracetamol and chlorzoxazone	82
Table 3.19 Interday precision test for mixture of paracetamol and chlorzoxazone standards.	83
Table 3.20 interday precision results for 80% of paracetamol and chlorzoxazone	83
Table 3.21 interday precision results for 100% of paracetamol and chlorzoxazone	83
Table 3.22 interday precision for 120% of paracetamol and chlorzoxazone	84
Table 3.23 Interday precision results summary for each paracetamol and chlorzoxazone	84
Table 3.24 Robustness results for paracetamol standards at optimum conditions	84
Table 3.25 Robustness results for chlorzoxazone standards at optimum conditions	85
Table 3.26 Robustness results for combined paracetamol and chlorzoxazone sample at optimum conditions	85
Table 3.27 Robustness results for paracetamol standard at increased temperature	85
Table 3.28 Robustness results for chlorzoxazone standard at increased temperature	85
Table 3.29 Robustness results for combined paracetamol and chlorzoxazone sample at increased temperature	86
Table 3.30 Robustness results for paracetamol standard at decreased temperature	86
Table 3.31 Robustness results for chlorzoxazone standard at decreased	86

temperature	
Table 3.32 Robustness results for combined paracetamol and chlorzoxazone sample at decreased temperature	86
Table 3.33 Robustness results for paracetamol standard at increased flow rate	87
Table 3.34 Robustness results for chlorzoxazone standard at increased flow rate	87
Table 3.35 Robustness results for combined paracetamol and chlorzoxazone sample at increased flow rate	87
Table 3.36 Robustness results for paracetamol standard at decreased flow rate	88
Table 3.37 Robustness results for chlorzoxazone standard at decreased flow rate	88
Table 3.38 Robustness results for combined paracetamol and chlorzoxazone sample at decreased flow rate	88
Table 3.39 Robustness results for paracetamol standard at increased organic solvent	88
Table 3.40 Robustness results for chlorzoxazone standard at increased organic solvent	89
Table 3.41 Robustness results for combined paracetamol and chlorzoxazone sample at increased organic solvent	89
Table 3.42 Robustness results for paracetamol standard at decreased organic solvent	89
Table 3.43 Robustness results for chlorzoxazone standard at decreased organic solvent	89
Table 3.44 Robustness results for combined paracetamol and chlorzoxazone sample at decreased organic solvent	90
Table 3.45 Robustness results for paracetamol standard at increased wavelength detection	90
Table 3.46 Robustness results for chlorzoxazone standard at increased wavelength detection	90
Table 3.47 Robustness results for combined paracetamol and chlorzoxazone sample at increased wavelength detection	90
Table 3.48 Robustness results for paracetamol standard at decreased wavelength detection	91
Table 3.49 Robustness results for chlorzoxazone standard at decreased wavelength detection	91
Table 3.50 Robustness results for combined paracetamol and chlorzoxazone sample at decreased wavelength detection	91
Table 3.51 Recovery results for paracetamol and chlorzoxazone at all robustness conditions	92
Table 3.52 Assay results for paracetamol and chlorzoxazone standards	92
Table 3.53 Assay results for combined paracetamol and chlorzoxazone sample	92
<b>Tables obtained from Validation results when using stainless steel Monolithic Column</b>	
Table 3.54 System suitability results for paracetamol and Chlorzoxazone	93
Table 3.55 Linearity result for paracetamol	93
Table 3.56 Linearity result for Chlorzoxazone	94
Table 3.57 Accuracy results for paracetamol and chlorzoxazone standards	97
Table 3.58 Accuracy results for paracetamol	97
Table 3.59 Accuracy results for chlorzoxazone	97
Table 3.60 Summary of accuracy results for paracetamol and chlorzoxazone	97
Table 3.61 Intraday precision results for paracetamol and chlorzoxazone mixed	98

standard	
Table 3.62 Intraday precision results for 80% paracetamol	98
Table 3.63 Intraday precision results for 100% paracetamol	98
Table 3.64 Intraday precision results for 120% paracetamol	98
Table 3.65 Intraday precision results for 80% chlorzoxazone	99
Table 3.66 Intraday precision results for 100% chlorzoxazone	99
Table 3.67 Intraday precision results for 120% chlorzoxazone	99
Table 3.68 Summary of intraday precision results for paracetamol and chlorzoxazone	99
Table 3.69 Interday precision results for mixture of paracetamol and chlorzoxazone standards	99
Table 3.70 Interday precision results for 80% of paracetamol and chlorzoxazone	100
Table 3.71 Interday precision results for 100% of paracetamol and chlorzoxazone	100
Table 3.72 Interday precision results for 120% of paracetamol and chlorzoxazone	100
Table 3.73 Interday precision results summary for each paracetamol and chlorzoxazone	100
Table 3.74 Robustness results for combined paracetamol and chlorzoxazone standards at optimum conditions	101
Table 3.75 Robustness results for combined paracetamol and chlorzoxazone sample at optimum conditions	101
Table 3.76 Robustness results for paracetamol and chlorzoxazone standards at increased temperature	102
Table 3.77 Robustness results for combined paracetamol and chlorzoxazone sample at increased temperature	102
Table 3.78 Robustness results for paracetamol and chlorzoxazone standards at decreased temperature	102
Table 3.79 Robustness results for combined paracetamol and chlorzoxazone sample at decreased temperature	102
Table 3.80 Robustness results for combined paracetamol and chlorzoxazone standards at increased flow rate	103
Table 3.81 Robustness results for combined paracetamol and chlorzoxazone sample at increased flow rate	103
Table 3.82 Robustness results for combined paracetamol and chlorzoxazone standards at decreased flow rate	103
Table 3.83 Robustness results for combined paracetamol and chlorzoxazone samples at decreased flow rate	104
Table 3.84 Robustness results for combined paracetamol and chlorzoxazone standards at increased organic solvent	104
Table 3.85 Robustness results for combined paracetamol and chlorzoxazone sample at increased organic solvent	104
Table 3.86 Robustness results for combined paracetamol and chlorzoxazone standards at decreased organic solvent	105
Table 3.87 Robustness results for combined paracetamol and chlorzoxazone sample at decreased organic solvent	105
Table 3.88 Robustness results for combined paracetamol and chlorzoxazone standards at increased wavelength detection wavelength detection	105
Table 3.89 Robustness results for combined paracetamol and chlorzoxazone	106

ample at increased wavelength detection	
Table 3.90 Robustness results for combined paraceamol and chlorozoxazone standards at decreased wavelength detection	106
Table 3.91 Robustness results for combined paraceamol and chlorozoxazone sample at decreased wavelength detection	106
Table 3.92 Robustness results for combined paraceamol and chlorozoxazone recovery at all robustness conditions	106
Table 3.93 Assay results for combined paraceamol and chlorozoxazone standard	107
Table 3.94 Assay results for combined paracetamol and chlorozoxazone sample	107

## List of Figures

Figure	Page
Figure 1.1: Modes of HPLC separation [18]. Where, LS: Liquid solid, SE: Size-exclusion, IE: Ion-exchange, AC: Affinity chromatography, BP: Bonded phase, LL: Liquid liquid, RP: Reversed phase, IS: Ion suppression, IP: Ion pair, MC: Metal complexation, ML: Micellar liquid and HI: Hydrophobic interaction.	2
Figure 1.2: Schematic diagrams depicting separation modes of (left) NPC and (right) RPC.	3
Figure 1.3: Reaction of silica gel with a functional group to produce a RP stationary phase.	4
Figure 1.4: SEM pictures of HPLC silica particles (5 $\mu$ m) and silica monolith	7
Figure 1.5 Dilution in chromatographic systems with a conventional (upper column) and narrow column (lower column). Both columns have the same axial dilution (band broadening). However, the increased ID of the conventional column gives an increase in radial dilution, which will give a decrease in signal intensity (lower sensitivity for concentration sensitive detectors).	9
Figure 1.6: A sensitivity comparison of different column i.d. for digested myoglobin.	12
Figure 1.7: Schematic representation of (a) packed, (b) WCOT, (c) SCOT and (d) PLOT cross section columns.	13
Figure 1.8: Experimental van Deemter curves, illustrate the dependence of the theoretical plate height on the flow velocity for columns packed with same type of particles of different average diameter	14
Figure 1.9: (a and b) SEM of a styrene based monolithic structure in a 75 $\mu$ m I.D. capillary column [87]. (c and d) SEM of a silica monolith inside a 100 $\mu$ m i.d. capillary column	16
Figure 1.10: Chromatograms obtained with different injectors. (A) Chromatogram obtained using a micro valve injector. (B) Chromatogram obtained using a conventional injector. Conditions: column, C18 (250mm x 1.5mm i.d.), mobile phase, acetonitrile/water (90/10, v/v%), flow rate, 0.1mL/min, injection volume, 1mL, detection, UV absorbance at 250nm with 1mL cell, sample solvent: acetonitrile. Peaks: 1 benzene, 2 naphthalene, 3 biphenyl, 4 fluorene, 5 anthracene	17
Figure 1.11: Schematic representation of the column switching system coupled with UV and/or MS	18
Figure 1.12: Effect of detector cell volume on separation efficiency: (A) 1 $\mu$ L cell; (B) 8 $\mu$ L cell. Experimental conditions: column, 250mm x 1.5mm i.d. C18 (5 $\mu$ m), mobile phase: acetonitrile/water (90/10, v/v%), flow rate, 100 $\mu$ L/min, injection volume, 1 $\mu$ L, detection, UV absorbance at 250nm. Peaks: 1 benzene, 2 naphthalene, 3 biphenyl, 4 fluorene, 5 anthracene	19
Figure 1.13: Influence of time constant on peak shape and sensitivity: (A) 0.2sec; (B) 2sec. Column, 50mm x 4.6mm i.d. C18 (3 $\mu$ m). Peaks: 1 $\alpha$ -tocopherol, 2 $\beta$ -tocopherol, 3 $\gamma$ -tocopherol, 4 $\delta$ -tocopherol	21
Figure 1.14: Effects of poor connecting tubing on separation efficiency: (A) properly connected tubing, (B) tubing seated improperly at either end of the column. Experimental conditions: column, 250mm x 1.5mm i.d. C18 (5 $\mu$ m), mobile phase, acetonitrile/water (90/10, v/v%), injection volume, 1 $\mu$ L, detection, UV absorbance at 250nm, detector cell volume, 1 $\mu$ L. Peaks: 1 benzene, 2 naphthalene, 3 biphenyl, 4 fluorene, 5 anthracene	22
Figure 1.15: Types of connectors for fused silica tubing and columns (low and high	23



Pressure).	
Figure 1.16: Photomicrograph of open pore polyurethane structure	24
Figure 1.17: SEM images of different types of porous chromatographic materials: (a) irregularly shaped silica particles, (b) spherical silica particles, (c) organic polymer monolith A (UNO S), (d) organic polymer monolith B (CIM Disk) and (e) silica based monolith (Chromolith)	28
Figure 1.18: Schematics for the preparation of monolithic capillary columns	31
Figure 1.19: Chemical structure of some monomers that can be used to form porous organic monolithic structures.	34
Figure 1.20: Examples of crosslinking monomers used for the preparation of porous polymer monoliths	35
Figure 1.21: Chemical structure of some reported initiators: azobisisobutyronitrile AIBN (1) [366–370], 2,2dimethoxy-2-phenylacetophenone DMPA (2) [175, 208], dibenzoyl peroxide BPO (3) and lauryl peroxide LPO (4)	36
Figure 1.22: SEM image of the porous structure of a typical monolithic silica column (up), and enlarged view of both macro and mesopores.	37
Figure 1.23: Column backpressure as a function of the flow rate. Backpressure comparison on conventional and monolithic column (silica) Circles denote Purospher C18 packed column; closed squares denote equipment pressure drop without the column; other symbols denote different monolithic columns, all in one line	38
Figure 1.24: Representative passage of the mobile phase through particulate media (a) and monoliths continuous support (b).	39
Figure 1.25: Typical calibration curve showing LOD, LOQ, LOL and dynamic range.	50
Figure 1.26 Chemical structures of (1a) paracetamol (1b) chlorzoxazone	51
Figure 2.1: Activation of inner wall fused silica.	62
Figure 2.2: Schematic representation of preparation procedure of monolithic columns.	63
Figure 3.1 Mechanical stability plots of the prepared column, backpressure as a function of acetonitrile flow rates	74
Figure 3.2 SEM images of the synthesized monolith bulk region at (A) x 2,000 and (B) x 8,000 603 magnification powers.	74
Figure 3.3 Mechanical stability plots of the prepared column, backpressure as a function of acetonitrile and water flow rates	75
Figure 3.4 SEM images of bulk region glycidyl polymethacrylate monolith column.	76
Figure 3.5 XL 2010 Graph of conc. in $\mu\text{g/ml}$ Vs average area of paracetamol	77
Figure 3.6 XL 2010 Graph of conc. in $\mu\text{g/ml}$ Vs average area of Chlorzoxazone	78
Figure 3.7 Specificity chromatogram for the Placebo of paracetamol and chlorzoxazone	79
Figure 3.8 Specificity chromatogram for the sample of paracetamol and chlorzoxazone	79
Figure 3.9 Specificity chromatogram for mixed standard of paracetamol and chlorzoxazone	79
Figure 3.10 XL 2010 Graph of conc. Vs average area of paracetamol	93
Figure 3.11 XL 2010 Graph of conc. in $\mu\text{g/ml}$ Vs average area of Chlorzoxazone	94
Figure 3.12 chromatogram for the Placebo of paracetamol and chlorzoxazone	95
Figure 3.13 chromatogram for the sample of paracetamol and chlorzoxazone	96
Figure 3.14 Specificity chromatogram for mixed standard of paracetamol and chlorzoxazone	96